進行性腎癌に対するInterferon-alpha(IFNα)と5FU(持続静注)併用療法

Abstract

進行性腎癌のうち評価可能病変を有する11例にIFNαの筋注と5FUの24時間持続静脈内注入療法を4週間施行した. 1)3例が口内炎などの消化器症状で治療を中止したため評価可能症例は8例であった. 2)8例中PRが2例, MRが2例, NCが2例, PDが2例であり, 奏効率は25%であった. 3)副作用は発熱, 倦怠感, 消化器症状の頻度が高く, 特に消化器症状は治療の続行が不可能になる場合もあった

Between May 1990 and April 1994, eleven patients with metastatic renal cell carcinoma received a combination therapy with interferon-alpha (IFN alpha) and 5-fluorouracil (5FU). IFN was administered intramuscularly six or ten million units three times per week for 4 weeks and 300 mg/m2 of 5FU was administered by continuous intravenous infusion daily for 4 weeks. Of 8 evaluable patients, two had a partial response (25%) two had a minor response (25%), and two had a stable disease (25%). The common side effects of the regimen were flu-like symptoms (91%), mucositis (64%) and leukopenia (75%). Three patients refused this therapy because of severe mucositis or stomatitis. Although the combination of IFN and 5FU in patients with metastatic renal cell carcinoma had some efficacy, this regimen had severe toxicity especially for the gastrointestinal (GI) tract. None of the patients could be administered the initially scheduled dosage of 500 mg/m2 of 5FU. The dose limiting factor of this regimen is considered to be GI symptoms.